Bugula neritina is of interest from a drug discovery perspective because its bacterial symbiont, Candidatus Endobugula sertula, produces the bryostatins, a group of around twenty bioactive natural products. The bryostatins are under investigation for their therapeutic potential directed at cancer, treatment of Alzheimer's disease, and HIV/AIDS, due to their low toxicity and antineoplastic activity.
Despite that, there is a challenge in the utilization of bryostatins in medical treatments, given that it is only found in small quantities in the organisms, making it unfeasible for the replication of the process. In addition, the symbiotic relationship of B. neritina and the bacteria Candidatus Endobugula sertula has not yet been searched enough, bringing difficulties for the biosynthetics in the study about the cultivation of this bacteria.